Business

Cathie Wood’s ARK Genomic Revolution ETF Buys Psychedelic StockShutterstock

Cathie Wood’s ARK Genomic Revolution ETF Buys Psychedelic Stock

,
Our resident Psychedelic Investor explains why this is an important moment for the psychedelics sector.

Cathie Wood and ARK Invest Buy a Psychedelic Stock!!! | $ARKG | Initial Reaction 🍄🍾

GUYS. IT HAPPENED. Cathie Wood and ARK Invest have invested in a Psychedelic Stock! Specifically, ARKG, or the ARK Genomic Revolution ETF have purchased atai Life Sciences (Nasdaq: atai)! Follow us on Twitter: @Psy_Invest @psy_holy @PsycSpotlight Follow us on Instagram: @psycbiz @psycspotlight To learn more about the emerging psychedelic industry, visit: https://psychedelicspotlight.com/ Last year, the Psychedelic Investor and the Reddit Page “ShroomStocks” managed to get the question of “would you ever invest in Psychedelic Stocks” asked to Cathie Wood of ARK Invest, and her answer was a dismissive NO. She said that ARK did not invest in binary stocks, though Kevin O’Leary, who was on the same panel disagreed. Well, it seems that time (and maybe Kevin O’Leary) have changed her mind. On Wednesday, February 9th, it was revealed that the Ark Genomic Revolution ETF, ticker symbol ARKG, had purchased 83,278 shares of ATAI. And while this only represents 0.01% of that fund’s total holdings, it does represent a big moment for the entire psychedelics industry. For better or worse, Cathie Wood has a huge voice among investors who like growth stocks, and next-generation technology stocks, which psychedelic stocks definitely represent. This will likely put more focus, not only on atai, but the entire psychedelics sector. I would not be surprised if companies such as MindMed (MMEDF) and Cybin (CYBN) also benefit from this. Perhaps, in the future, Ark will also buy these companies. Hopefully, this is but an opening position, and ARKG continues to buy psychedelic stocks such as atai and MindMed. Ideally, I would also like to see the flagship ETF, ARKK, also invest in psychedelic Stocks. #CathieWood #ARKG #PsychedelicStocks
DMT Vape Pen Patent Illustrates a Big Problem in the Psychedelics IndustryShutterstock

DMT Vape Pen Patent Illustrates a Big Problem in the Psychedelics Industry

Problematic patents have serious implications for the entire psychedelics industry.
Is Investing in Psychedelic Stocks a Good Idea? A ThesisShutterstock

The Thesis for Investing in Psychedelic Stocks

,
Our resident Psychedelic Investor makes the case why the psychedelic sector may yield big returns.
4 Tips for Investing in Psychedelic Stocks During a Market DownturnShutterstock

4 Tips for Investing in Psychedelic Stocks During a Market Downturn

,
Friendly advice for responsibly managing speculative bets on psychedelic stocks that may rise like a phoenix or burn to the ground.

Psychedelic Business Spotlight – February 4

,
Levitee Labs Announces Interim CEO and Board of Directors ShuffleThis week in psychedelic business news, Levitee Labs Inc. (CSE: LVT) (OTC: LVTTF) (FSE: 7H7), a psychedelic medicine and wellness company, has appointed Philip van den Berg as…
Sponsored by Mindset Pharma

Why Mindset Pharma’s Deal with Big Pharma Is a Big Deal for Psychedelics

The partnership with global pharmaceutical company Otsuka positions the psychedelic medicine company as a leader in the industry.
Psychedelic Business Spotlight — January 28

Psychedelic Business Spotlight — January 28

,
This week in psychedelic business news: A major player begins manufacturing; another rebrands; and one of the biggest gets bigger.

MindMed gets FANTASTIC News from the FDA, Causing its Stock to Skyrocket (MNMD/MMED) | Project Lucy

Follow us on Twitter: @Psy_Invest @psy_holy @PsycSpotlight Follow us on Instagram: @thepsychedelicinvestor @psycspotlight To learn more about the emerging psychedelic industry, visit: https://psychedelicspotlight.com/ MindMed (Nasdaq: MNMD, NEO: MMED) today announced that their Flagship Program, Project Lucy, has been given the green light from the FDA. MindMed is set to start a phase 2b Clinical Trial treating Generalized Anxiety Disorder with MM-102. In response, MindMed’s stock has SKYROCKETED! It is up 39% at the time of writing and it could go higher. The psychedelic stock has been battered over the last 8 months, so it is good to see positive news affecting the price. MindMed is a company attempting to treat mental health conditions such as Anxiety and Depression with Psychedelic Therapies. Can psychedelics relieve anxiety and treat mental health? MindMed wants to know! #MNMDstock# MindMed #Psychedelics

© 2023 Psychedelic Spotlight. | Owned and operated by PSYC Media Corporation, Inc. a US publicly traded company (OTCPink: PSYC) | All Rights Reserved.